MabVax Therapeutics Holdings, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported loss from operations of $5,092,314 compared to $4,204,295 a year ago. Net loss allocable to common stockholders was $5,354,854 or $0.85 per basic and diluted share compared to $4,404,770 or $1.12 per basic and diluted share a year ago.